Lewy body dementia to fit precisely with ATH434 use. If they are also finding ATH434 stabilises or even improves brain mass loss (like in the 202 study from 6-12months), than that will also bode incredibly well for ATH434.
I would also assume the MRI AI technology they are utilising can also assist monitor regions of the brain affected by dementia and other neurodegenerate diseases.
Alterity is secretly and precisely opening ATH434 to a substantially wide number of neurodegenerate diseases, only a matter of time till this baby biotech booms.
MOO.
ATH Price at posting:
0.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)